Ernexa Therapeutics Inc. — Investor Relations & Filings
Ernexa Therapeutics Inc. is a biopharmaceutical company developing cell therapies for advanced cancer and autoimmune diseases. The company's core technology platform engineers induced pluripotent stem cells (iPSCs) and differentiates them into induced mesenchymal stem cells (iMSCs). These engineered iMSCs are designed as scalable, off-the-shelf treatments that leverage the natural ability of MSCs to home to sites of tumors or inflammation. Once at the target site, the cells deliver therapeutic payloads, such as cytokines, to modulate the immune system. The company's lead candidate, ERNA-101, is being developed for the treatment of ovarian cancer. Its pipeline also includes ERNA-201, a cell therapy designed to target inflammation in autoimmune diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Major Shareholding Notification 2026 | 2026-05-14 | English | |
| ARS - Ernexa Therapeutics Inc. (0000748592) (Filer) | 2026-05-11 | English | |
| DEFA14A | 2026-05-11 | English | |
| DEF 14A | 2026-05-11 | English | |
| 10-Q - Ernexa Therapeutics Inc. (0000748592) (Filer) | 2026-05-11 | English | |
| 8-K | 2026-05-04 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46086876 | Major Shareholding Notification 2026 | 2026-05-14 | English | ||
| 45003027 | ARS - Ernexa Therapeutics Inc. (0000748592) (Filer) | 2026-05-11 | English | ||
| 46086834 | DEFA14A | 2026-05-11 | English | ||
| 46086868 | DEF 14A | 2026-05-11 | English | ||
| 45001283 | 10-Q - Ernexa Therapeutics Inc. (0000748592) (Filer) | 2026-05-11 | English | ||
| 46086896 | 8-K | 2026-05-04 | English | ||
| 46086900 | DEF 14C | 2026-04-13 | English | ||
| 46086907 | PRE 14C | 2026-04-01 | English | ||
| 46086912 | Regulatory Filings 2026 | 2026-03-31 | English | ||
| 33035304 | S-3/A - Ernexa Therapeutics Inc. (0000748592) (Filer) | 2026-03-24 | English | ||
| 33002553 | 8-K - Ernexa Therapeutics Inc. (0000748592) (Filer) | 2026-03-20 | English | ||
| 46086943 | S-3 | 2026-03-13 | English | ||
| 46087042 | 10-K | 2026-03-13 | English | ||
| 32880604 | 8-K - ERNEXA THERAPEUTICS INC. (0000748592) (Filer) | 2026-02-26 | English | ||
| 46087044 | Major Shareholding Notification 2026 | 2026-02-18 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Ernexa Therapeutics Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35259/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35259 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35259 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35259 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35259}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Ernexa Therapeutics Inc. (id: 35259)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.